NCT06452095View on ClinicalTrials.gov

Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition

NANot yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Long COVIDPost Acute Sequelae of COVID-19Post-COVID-19 Condition

Interventions

DEVICE

Hyperbaric Oxygen therapy

The SECHRIST INDUSTRIES mono-place Hyperbaric Chambers OR Sigma Series mono-place Hyperbaric Chambers

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT06452095 - Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition | Biotech Hunter | Biotech Hunter